The history of (-)deprenyl the first selective inhibitor of type B monoamine oxidase

Voprosy Meditsinskoj Khimii

Volumn 43, Issue 6, 1997, Pages 490-493

  Knoll, J ^a  

^a SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

Author keywords

( ) deprenyl; Catecholamine activity enhancer; Dopamineergic systems; Neuroprotection; Selective inhibitor of MAO B

Indexed keywords

EID: 3943074534     PISSN: 00428809     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (89)

1. Barger G., Dale H.H.: J. Physiol. (Lond.) 1910; 41, 19-59
2. Birkmayer W., Hornykiewicz O.: Wien. Klin. Wochenschrift., 1961; 73, 787-788
3. Birkmayer W., Hornykiewicz O.: Arch. Psychiat Nervenkrh., 1962; 203, 560-564
4. Birkmayer W., RiedererP., Ambrozi L., Yondim M.B.H.: Lancet, 1977, 1, 439-443
5. Birkmayer W. Knoll J., Riederer P. Youdim M.B.H.,Hars V., Marion J.: J. Neural Transm., 1985; 64, 113-127
6. Blackwell B.: Lancet 1963, II, 849-851
7. Burn J.H., Rand M.J:. J. Physiol., (Lond.) 1958; 144, 314-336
8. Carrillo M.C., Kanai S., Nokubo M., Kitani K.: Life Sci., 1991; 48, 517-521
9. Carrillo M.C., Kanai S., Nokubo M., Ivy G.O., Sato Y., Kitani K:. Exp. Neural., 1992; 116, 286-294
10. Clough C.G.: Parkinson's disease management. Lancet, 1991; 337, 1324-1327
11. Cohen G., Pasik P., Cohen B., Leist A., Mitileneou C. Yahr M.D.: Eur. J. Pharmacol., 1984; 106, 209-210
12. Colombo C., Spica P.: Gazz. Chim. Ital., 1875; 5, 124-125
13. Ehringer H., Hornykiewicz O.: Wien. Klin. Wochenschrift., 1960; 38, 1236-1239
14. Elsworth J.D., Glover V., Reynolds G.P., Sandier M., Less A. J., Phuapradit P., Shaw K.M., Stern G.M., Kumar P.: Psychopharmacology, 1978; 57, 33-38
15. Finnegan K.T., Skratt J.J., Irvin L, DeLanney L.E., Langston J.W:. Eur. J. Pharniacol., 1990; 184, 119-126
16. Fischer E., Heller B., Miry,A.H.: Arzneimittel-Forschung, 1968; 18, 1486
17. Graham D.G.: Arch. Pathol. Lab. Med., 1979; 103, 359-362
18. Goad D.L., Davis C.M., Leim P., Fuselier C.C., McCormack J.R., Olsen K.M. J.: Clin.Psychiatry, 1991; 52, 342-345
19. Hall D. W.R., Logan B. W., Parsons G.H.: Biochem. Pharmacol., 1969; 18, 1447-1454
20. Horsing R.G., Magyar K., Tekes K., Vizi E.S., Knoll J.: Pol. J. Pharmacol. Pharm.,1979; 31, 297-307
21. Johnston J.P.: Biochem Pharmacol, 1968; 17, 1285-1297
22. Joseph J.A., Berger R.E., EngelB.T.: J. Gerontol., 1978; 33, 643-650
23. Kitani K., Kanai S., Sato Y., Ohta M., Ivy G.O., Carillo M.C.: Life Sci., 1992r 52, 281-288
24. Knoll J.: In: Monoamine oxidase and its inhibition. Ciba foundation Symposium 39 (new series) Eds. Wolstenholme G.E.S., Knight J. Elsevier/North Holland, Amsterdam, 1976; pp. 131-161
25. Knoll J:. J. Neural Transm.,1978a; 43, 177-198
26. Knoll J.: In: Enzyme-activated irreversible inhibitors, Eds. Seiler N., Jung M. J., Koch-Weser J., Elsevier, Amsterdam, Holland Biomedical Press, 1978b; pp. 253-269
27. Knoll J.: TINS, 1979; 1, 111-113
28. Knoll J.: In: Enzyme inhibitors as drugs. Ed. Sandler M., The MacMillan Press Ltd, London, 1980; pp.151-171
29. Knoll J.: In: Monoamine oxidase inhibitors. The state of the art. Eds. Youdim M.B.H., Paykel ES. Wiley, New York, 1981, pp. 45-61
30. Knoll J.: In: Strategy in drug research. Ed. Keverling Buisman JA. Elsevier, Amsterdam, 1982, pp.107-135
31. Knoll J.: Acta Neurol. Scand., 1983; Suppl. 95, 57-80
32. Knoll J: Mech. Ageing and Dev. 1985, 30, 109-122
33. Knoll J: In: Dopamine, ageing and diseases, Eds: Borsi J., Kerecsen L., Gyorgy L. Pergamon Press - Akadamiai Kiado, Budapest, 1986a, pp.7-26.
34. Knoll J.: J. Neur. Trans. 1986b, Suppl: 22, 75-89.
35. Knoll J.: In: Movement disorders, Eds: Shah N.S., Donald A.G.. Plenum Press, New York, 1986c, pp:53-81.
36. Knoll J.: J. Neural Transm., 1987; 25, 45-66
37. Knoll J.: Mech. Ageing and Dev., 1988; 46, 237-262
38. Knoll J.: Acta Neurol Scand., 1989; 126, 83-91
39. Knoll J.: Advances Neurol., 1990; 53, 425-429
40. Knoll J.: Medicinal Res. Rev., 1992a, 12, 505-524
41. Knoll J.: Pharmacol. Toxicol., 1992b, 70, 317-321
42. Knoll J.: J. Am. Geront. Soc., 1992e, 40, 839-847
43. Knoll J.: J. Neural. Trans. 1993a, Suppl. 40, 69-91
44. Knoll J.: In: Inhibitors of monoamine oxidase B. Ed. Szelenyi I., Birkhauser Verlag, Basel, 1993b, pp.146-168
45. Knoll J.: In: Monoamine oxidase. Ed. Yasuhara H., VSP, Utrecht, 1993c, pp. 197-217
46. Knoll J.: Pharmacol Toxicol. 1994, 75, 65-72
47. Knoll J.: Biomed. Pharmacother. 1995, 49, 187-195
48. Knoll J., Ecseri Z., Kelemen K.,.Nievel J., Knoll B.: Arch. int. Pharmacodyn. Ther., 1965; 155, 154-164
49. Knoll J., Vizi E.Sz., Somogyi Gy.: Arzneimittel-Forschung, 1968; 18, 109-112
50. Knoll J., Magyar K.: Adv. Biochem Psychopharmacol., 1972; 5, 393-408
51. Knoll J., Yen T.T., Dally J.: Mod. Probl. Pharmacopsychiat., 1983; 19, 135-153
52. Knoll J., Dally J., Yen T.T.: Life Sci., 1989; 45, 525-531
53. Knoll J., Knoll B., Torok Z., Timor J., Yasar S.: Arch. Int. Pharmacodyn. Ther., 1992a; 316, 5-29
54. Knoll J., Toth V., Kummert M., Sugar J.: Mech. Ageing and Dev., 1992b; 63, 157-163
55. Knoll J., Miklya I: Arch. Int. Pharmacodyn. Ther. 1994, 328, 1-15
56. Knoll J., Yen T.T., Miklya L: Life Sci. 1994, 54, 1047-1057
57. Knoll J., Miklya I., Life Sci., 1995, 56, 611-620
58. Knoll J., Miklya I., Knoll B., Marky R., Kelemen K.: Life Sci., 1996a; 58, 817-827
59. Knoll J., Miklya I., KnollB., Marky R., Racz D.: Life Sci., 1996b; 58, 2101-2114
60. Knollema S., Aukema W., Horn H., Horf J., Gert J., Horst T.: Stroke, 1995; 26, 1883-1887
61. Mangoni A., Grassi M.P., Frattola L., Piolti R., Bassi S., Motta A.: Eur. Neurol., 1991; 31, 100-107
62. Mann J.J., Gershon S.: Life Sci., 1980; 26, 877-882
63. Martin C.: In: Handbook of Sexology. Eds. Money J., Musaph H., Elsevier, Amsterdam, 1977, pp.813-824
64. Martini E., Pataky I., Szilagyi K., Venter V.: Pharmacopsychiatry, 1987; 20, 256-257
65. Milgram M.W., Racine R.J., Nellis P., Mendoca A., Ivy G.O.: Life Sci. 1990, 47, 415-420
66. Nakajima T., Kakimoto Y., Sana I.: J.Pharm., 1964; 143, 319-325
67. Parkinson Study Group. New Engl. J. Med., 1989; 321, 1364-1371
68. Parkinson Study Group. New Engl. J. Med., 1993; 328, 176-183
69. Parkinson Study Group. Ann Neurol., 1996, 39, 37-45
70. Piccinin G.L., Finali G.C., Piccirilli M., Clin. Neuropharmacol., 1990; 13, 147-163
71. Prinzmetal M., Bloomberg W:. JAMA, 1935; 105, 2051-2054
72. Rinne J.O., Roytta M., Paljarvi L. Rummukainen J., Rinne U.K.: Neurology, 1991; 41, 859-861
73. Rogers J., Bloom F.E.: In. Handbook on the Biology of Aging, Eds. Finch C.E., 73. Schneider E.L., Van Nostrand Reinhold, New York, 1985, pp; 645-657
74. Severson J.A., Finch C.E.: Brain Res., 1980; 192, 147-162
75. Tatton W.G., Greenwood, C.E. J. Neurosci. Res., 1991; 30, 666-672
76. Tattoh W.G., Yu W.Y.L., Holland D.P., Tai C., Kwan M.: J. Neurochem., 1994; 63, 1572-1575
77. Taylor J.D.: Nature, 1960; 187, 941-943
78. Thal L.J., Horowitz S.G., Dvorkin B., Makham H.H.: Brain Res., 1980; 192, 185-194
79. Tariot P.N., Cohen R.M., Sundcrland T., Newhouse P.A., Yount D., Mellow A.M.: Arch. Gen. Psychiatry, 1987; 44, 427-433
80. Tetrud J.W., Langsten J. W.: Science, 1989; 245, 519-522
81. Tyth V., Kummert M., Sugar J., Knoll J.: Mech. Ageing and Dev., 1992; 63, 215-221
82. Tringer L., Hails G., Varga E.: In: V. Confcrentia Hungarica pro Therapia et Investigatione in Pharmacologia. Ed.Leszkovszky G., Akad. Kiado, Budapest, 1971, pp. 111-114
83. Varga E.: In: III. Conferentia Hungarica pro Therapia et Investigatione in Pharmacologia, Ed. Dumbovich B., Akad. Kiado, Budapest, 1965, pp. 197-201
84. VargaE., Tringer L.: Acta Med. Acad. Sci. Hung., 1967; 23, 289-295
85. Vizuete M.L, Steffen V., Ayala A., Cono J., Machado A.: Neurosci Lett., 1993; 152, 113-116
86. Wu R.M., Chiuech C.C., Pert A., Murphy D.L.: Europ. J. Pharmacol., 1993; 243, 241-247
87. Yasar S., Winger G., NickelB., Schulze G.. Goldberg S.R.: In: Inhibitors of Monoamine Oxidase B. Ed. I. Szelenyi, Birkhauser Verlag, Basel, 1993, 215-233
88. Yu W.Y., Holland D.P., Talion W.G.: Experimental Neurology, 1994; 126, 233-246 89
89. Zhang, F., Richardson P.M., Holland D.P., Gno Q., Tatton W.G.: J. Neurosci. Res., 1995; 40, 464-570